Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (9891)	5/10/1999 11:49:00 PM
From: Gary L. Kepler	Read Replies (1) \| Respond to of 17367

For whatever it is worth from the ICOS thread: Message 9454754 "There is an article in the most recent issue of Genetic Engineering News that discusses the problems that have plagued other attempts at anti-sepsis drugs. It highlighted the fact that sepsis is a complex process that has "redundant" mechanisms, such that intervening at one point doesn't solve the entire problem. I believe that it mentioned that there are about a dozen drugs currently in phase II and later trials for sepsis, and that there are about a dozen drugs that have failed in clinical trials. ICOS, of course, is not mentioned, since IC14 is just barely into the clinics. I don't know enough about the specific sepsis mechanisms and how CD14 plays a role in these processes to speculate about its chances for success, but it's clearly going to be an uphill fight, and it wouldn't surprise me at all if ICOS stumbles on this one. It'll be some time before anyone knows anything."